Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration

Kyle Blankenship

Bayer and discovery outfit Evotec have long been bosom buddies, cycling through partnerships for the better part of a decade. But now, Bayer is dumping …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration